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DDiscussion
Dr Michael Argenziano (New York, NY).My disclosure is that
I am a consultant for Estech.
Ralph, you and your group need to be congratulated for another
outstanding presentation in the area of atrial fibrillation, and you
have certainly carried on Dr Cox’s tradition at St. Louis very
well. Thank you for the manuscript in advance, as that was obvi-
ously very helpful.
As you noted, the Cox maze procedure was really the gold stan-
dard and really remains the gold standard for the treatment of atrial
fibrillation; however, it was never adopted in any sorts of great
numbers because of its complexity. As you know, since the late
1990s, a number of more ‘‘limited’’ procedures using a variety
of energy sources have been developed and, unfortunately, there
have been many energy sources, many lesion sets, many selection
criteria, andmany definitions of success, et cetera, to the point that,
although we have been doing this for over 10 years, many ques-
tions remain. Those are, what are the best energy sources? Are
there certain energy sources that are better in certain applications
than others? What are the better lesion sets? Should we be using
a box versus an isolated pulmonary vein approach? Should we
be doing left atrium only or both atria, as you did here? How do
we select patients? And then, most importantly, I believe, how
do we follow these patients up? Because although you did a tre-
mendous job in following up these patients, the total percentage
of the time that these patients are alive that you have monitored
is really very small, and especially because you have such a high
paroxsymal A-fib component, how dowe knowwhat these patients
are doing when they are not being monitored?
Your findings in a large group of patients with atrial fibrillation,
which were a mix of both paroxsymal and nonparoxysmal patients
but which were mostly condominant, were that a box lesion is bet-
ter, and I certainly would agree with that, and we have been saying
for years and many of us have been saying that a box lesion just
electrophysiologically makes more sense, because not only does
it eliminate the triggers of atrial fibrillation that occur within the
pulmonary veins but it also acts to compartmentalize the left
atrium and reduce the ability of the substrate to contribute, as
Dr Cox taught us.
You found that a large left atrium is worse, and we concur with
that and we have actually published that as well, and it makes good
sense that probably the best surrogate of the degree of remodeling
that exists in an atrium is not duration or anything else or age but
rather the size of the atrium.The Journal of Thoracic and CaAnd then, finally, you found that early arrhythmias predicted
a worse outcome, which actually was a surprise to us, because
we looked at this as well and we actually have found that there
is no difference and, for that reason, have not really been very
aggressive about managing the early arrhythmias, although I
would like to hear more from you about that.
So, you had excellent overall success. You used right-sided
lesions universally, which we would agree with, and, again, you
had excellent follow-up. I have 3 questions for you.
First is, you have shown that the box lesion is better, but we know
that the majority of the patients that you operated on in this series
were concomitant, although a third were stand-alone procedures.
You and I have spoken before, and I know that you have done
many more than 95 stand-alone atrial fibrillation ablations. So,
therefore, you must be doing some of the standalone patients with
lone atrial fibrillation with a purely epicardial pulmonary vein bipo-
lar clamp technique. If so, how did you choose those patients and
why did the patients in this series get a more extensive lesion set?
Dr Damiano. That is an excellent question. Just to be as quick
as possible, we have done a significant number of the epicardial
approaches. We favor the bipolar clamps, and that has been most
of our experience. We initially performed the procedure on
a wide group of patients, though we have had, like others, poor re-
sults in patients with persistent or long-standing atrial fibrillation.
We are no longer offering this operation to this group because of
the poor results. And, to be honest with you, we cannot find any
device in our research laboratory capable of making reliable linear
lesions on the beating heart. I do not think there is one on the mar-
ket right now. However, we are initiating some hybrid approaches
with our electrophysiologists to help us overcome some of these
shortcomings. At present, we would consider patients with parox-
ysmal atrial fibrillation and a left atrial diameter of less than 5 cm
as good candidates for pulmonary vein isolation done thoraco-
scopically or with small incisions. Our success rates have not
been quite as high as with a full Maze procedure. The last time
we looked, it was about 75%. This is not bad, and you could
view it as part of a staged procedure. So we do offer that.
We give our patients full informed consent. We let them look at
our published results and our database results and let them choose
between the procedures. As we both know, some patients go for
a minimally invasive approach and some patients, particiularly if
they have failed a number of catheter ablations, just want to be
cured and they will go for a more complete procedure. You can
do the full maze IV, similar to our previous discussion, through
a right minithoracotomy. It is a lot easier than doing mitral valve
repair and with present devices it can be done very well. I agree,
you have to tailor your procedure to each specific patient.
I would caution those people who are doing epicardial pulmo-
nary vein isolation as their only procedure for atrial fibrillation
to be very careful that the patient’s arrhythmia is not actually atrial
flutter. This is quite common in failed catheter ablations, which
now make up over half of our stand-alone experience. You should
study them or make sure you have a qualified physician review
their EKGs and Holter monitors. Because if they have recurrent
flutter, which is not unusual, the only operation you can do is
a complete Maze procedure.
DrArgenziano. I would agreewith that. And, in fact, at Colum-
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Depicardial operation to patients with either multiple failed abla-
tions, enlarged atria, poor ejection fraction, and we reserve that
really to the purely early paroxsymal patients, which, unfortu-
nately, are exceedingly fewer and fewer because of the success
of catheter ablation.
Two brief questions. If earlier tachyrhythmias in the periopera-
tive period are a predictor of failure, what are you doing to either
treat that or to study those patients? In other words, do you think
that early arrhythmias predict failure because atrial fibrillation in
the perioperative period begets atrial fibrillation or do you think
that early atrial fibrillation is simply a surrogate for incomplete le-
sions?
Dr Damiano. That is an excellent question, Mike, and I can’t
really answer it. As you know, we published in Circulation in
2005 our maze III experience in which early arrhythmias were
not a predictor of late failure. It has turned out to be a predictor
in this study, and the only thing I can tell you is we now have
a much stricter definition of failure in that any patients who were
on antiarrhythmic drugs were considered a failure. So we have es-
tablished a more strict definition and perhaps that is allowing us
some more discriminatory ability.
My own feeling is it is not an incomplete lesion set, and we, like I
am sure you do, test for conduction block. The pulmonary vein
isolation is tested in every patient we are able cardiovert, which is
over 90% of this patient cohort. I think that early arrhythmias are
a marker of a worse atrial substrate, probably increased atrial fibro-
sis.We are doing a lot sicker patients and, like you say, I completely
agree, left atrial diameter is a really good surrogate for atrial remod-
eling. As I have thought about this more, I am not even sure that
being aggressive with atrial reduction will be enough in some of
these patients. There is a group of patients that I am convinced
we shouldn’t probably be operating on because of end-stage atrial
myopathy. In terms of restoring sinus rhythm, we are pretty aggres-
sive. We usually delay early cardioversion, but at 1 month we ag-
gressively attempt to restore sinus rhythm in all of those patients.
Dr Argenziano. The last question is about follow-up, and that
really I think winds up being the most interesting part of this entire
area. As you know, the Cardiothoracic Surgery Trials Network,
which is an NIH network grant, is currently involved in a random-
ized study looking at atrial fibrillation ablation, and one of our
main interests in that trial is really to figure out how can we im-
prove the way that we follow up these patients. How can we calcu-
late not just things like incremental A-fib incidents but rather
things like atrial fibrillation burden? And so what do you think
about implantable devices and transtelephonic monitoring and
ways to even increase even the excellent follow-up that you have?
Dr Damiano. I think that is an excellent point and a relatively
unanswered question. We have looked at our data and when we
eliminated the patients who just had ECG follow-up, it did not im-
pact the success rate. Unfortunately, the ECG follow-up group was
generally in the early part of our series when we did the nonbox
lesion, so it may have confounded the analysis.
I agree with you, monitoring remains a big question mark. I do
feel an EKG alone is not adequate in 2010. We are presently start-
ing a clinical trial with the Reveal device by Medtronic, which is
an implantable device, which would allow you almost continuous
monitoring. The question is how valuable this is going to be. What
if a patient has a minute of atrial fibrillation in a month? What120 The Journal of Thoracic and Cardiovascular Surgshould we do about that? I think it is going to make management
interesting.
I think that is something that I hope the NIH trial answers and,
as we gain more experience with these new implantable devices,
we may be able to understand exactly what the right thing to do is.
Dr Argenziano. Congratulations on a great study, Ralph.
Dr Richard Shemin (Los Angeles, Calif). Another major con-
tribution to the outcomes and work that you have done at Wash U
for A-fib. Obviously, we all agree that transmurality is important. I
think you just mentioned that in over 90% of the cases you do intra-
operative testing.
A technical question: How many times do you have to reapply
the clamp a second or a third time?
DrDamiano.Wewere one of the first groups to put out aword of
caution that we occasionally required 8 or 9 clamp applications to
isolate the pulmonary veins with the early versions of some of these
bipolar devices. With the 2 present versions, the Medtronic Cardio-
blate and the AtriCure Synergy clamps we found, that both have
excellent results. In general, I would say that they are over 90% ef-
fective with a single ablation when judged by the creation of con-
duction block. We are in a clinical trial with 1 of the devices
where we are testing this question. While I haven’t seen the multi-
center data, our own data has shown an over 95% success rate in cre-
ating conduction block with a single ablation, but it is not 100%.We
do 2 ablations for every lesion and then test by pacing from each
pulmonary vein. One of the reasons we don’t have data in all
patients for exit and entrance block is that we have a number of pa-
tients who either have a left atrial thrombus, which I would not rec-
ommend cardioversion because of the potential for emboli, or in
whom we are unable to restore sinus rhythm with cardioversion.
Dr Shemin. Since early recurrence of atrial fibrillation or other
arrhythmias is an adverse predictor, what is your specific postop-
erative protocol as far as antiarrhythmic drugs and early cardiover-
sion?
Dr Damiano.We have not changed any of our protocols based
on the results of this study, at least at the present time. Every pa-
tient that comes out of surgery, once they restore their sinus rhythm
is started on antiarrhythmic drug. Our drug of choice is amiodar-
one or whatever drug they tolerated preoperatively, and we
continue that for 2 months.
We have been aggressive with cardioversion, but ideally we
usually delay cardioversion for 3 to 4 weeks to let all the inflam-
mation subside.We found, as opposed to postoperative atrial fibril-
lation in patients undergoing CABG for instance, a lot of these
patients do not respond to early cardioversion. If it is not success-
ful, it can be upsetting to the patient.
When we see the patients back in a month, if they are in an atrial
flutter or fibrillation we will arrange cardioversion. I arrange it
myself. I don’t leave it up to the referring cardiologist.
Dr Shemin. Final question: Is there any role for the Cox maze
III procedure?
Dr Damiano. We talked about that in the panel, and at our in-
stitution right now, no, I don’t see any role for it.
Dr Thorsten Hanke (Luebeck, Germany). Congratulations on
your results. Just one question. Your more intensified monitoring,
that was about 25% of the patients?
Dr Damiano. Seventy percent of the entire population had ei-
ther 24-hour Holters or more prolonged monitoring. After 2006,ery c January 2011
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Dwhen the guidelines were actually published, 94% of patients had
prolonged monitoring.
Asmanyof youknow, if you follow large numbers of patientswith
atrial fibrillation, it is hard enough to get them to comeback. It can be
harder and harder as you try to get longer periods ofmonitoring. But,
yes, the majority of patients here had prolonged monitoring.
Dr Hanke. Did you see any difference with your more
prolonged observations than with the short-term ones? And keep
in mind that, even with a 14-day Holter strategy, you only have
a sensitivity of about 69 to 70%. So don’t you think it is time for
continuous monitoring, never mind whether it is Medtronic, Bio-
tronic, whatsoever, for all the patients?
Dr Damiano. I think it is an excellent point and to truly define
failure rates we will need to use such devices. But, as you know,
certainly at least in the United States, there have not been small im-
plantable devices available until recently and the reimbursement
has been a problem. So it has not been a viable option. But I agree,
and we will learn a lot from continuous monitoring.
However, as I said in my previous comment, if you took out
from our series the patients who had ECG only, using prolonged
monitoring did not result in a significant change in our failure
rate. However, I totally agree with you, and there are certainly
a number of studies in the electrophysiology literature and a few
from our literature that would suggest that, the more you monitor,
the more arrhythmias you will discover.
I will just put a note of caution for those of you who follow these
patients. We are following over 500 to 600 patients right now, and
what we would do with continuous monitoring in 500 patients. An
army of people would need to deal with all this data. There may
be medicolegal issues if, for instance, a patient had a 1-minute epi-
sode of atrial fibrrillation andwedidn’t do anything butwehappen to
have the electrograms stored in some computer warehouse. It is not
a trivial process.We arewrestling with what we are going to dowith
this mountain of data. We will need some help with it. But I totally
agree with your point there, and I think it will be an advance.
Dr Masashi Komeda (Kyoto, Japan). Congratulations on
a beautiful study. As you mentioned, left atrial diameter is so
important. We did a study of atrial reduction, Cox maze III proce-The Journal of Thoracic and Cadure, and we published the data from JTCVS twice. When we did
a volume reduction one third as big as before the surgery, the
defibrillation rate was quite high. I want to share your comment
on that.
Dr Damiano. I am aware of your excellent work and certainly
in my conclusions mention that we need to maybe adapt a more
aggressive atrial reduction procedure in patients with large left
atria to improve our success rates. We also may need a more
extended lesion set.
I will tell you, there is a subset of those patients that probably no
matter what you do, you won’t be able to cure them. They have
remodeled their atrium and they are so fibrotic that really no
amount of reduction will work. DrMadison Spach at Duke showed
that in elderly patients with atrial fibrosis that they can maintain
atrial fibrillation in a single trabeculae crossing the right atrium.
These patients we shouldn’t operate on, and perhaps MRI or
body surface mapping may help us identify this substrate before
the operation. But I acknowledge your work, and we are going
to try a little more aggressive reduction procedure in the future,
similar to what you have published.
Dr Komeda. Thank you. About that issue, maybe you are right
for some patients, but for some others, interestingly, the left atrium
keeps shrinking 1 year after surgery; it just keeps shrinking. So
maybe some patients still have a chance to have that type of reverse
remodeling and a better outcome of defibrillation.
Dr Damiano. I agree with you. It is trying to discriminate who
is going to get better and who isn’t. That would be very helpful be-
fore we put them through this surgery.
DrMarco Zenati (Pittsburgh, Pa). I enjoyed your presentation
and congratulations, especially for bravely adopting the guidelines
for both efficacy and follow-up. My question about the intensity of
the follow-up was already answered. I just want to make a brief
comment about the fact that your outcomes are based on a single
procedure and, if the guidelines were meant to compare surgical
versus catheter ablations, it is important that we compare single
procedures to single procedures.
Dr Damiano. I agree completely, but you need to be talking to
electrophysiologists, not me. They never like to do that.rdiovascular Surgery c Volume 141, Number 1 121
